Intermedin inhibits vascular calcification by increasing the level of matrix γ-carboxyglutamic acid protein
Authors:
- Ming-Jiang XuMXMing-Jiang Xu
- Xu TengXTXu Teng
- Ye Bo ZhouYZYe Bo Zhou
- Li ChenLCLi Chen
- Yi ZhuYZYi Zhu
- Xian WangXWXian Wang
- Chao Shu TangCTChao Shu Tang
- Yong Fen QiYQYong Fen Qi
- 12 November 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 85 (4) , 864-873
Abstract
Aims Vascular calcification (VC) is highly associated with increased morbidity and mortality in patients with advanced chronic kidney disease. Paracrine/autocrine factors such as vasoactive peptides are involved in VC development. Here, we investigated the expression of the novel peptide intermedin (IMD) in the vasculature, tested its ability to prevent VC in vivo and in vitro , and examined the mechanism involved. Methods and results Rat VC was induced by administration of vitamin D3 plus nicotine (VDN). IMD (100 ng kg−1 h−1) was systemically administered by a mini-osmotic pump. VDN-treated rat aortas showed lower IMD content and increased expression of its receptors, along with increased vascular calcium deposition and alkaline phosphatase (ALP) activity. Low IMD levels were accompanied by increased calcium deposition in human atherosclerotic plaques. In vivo administration of IMD greatly reduced vascular calcium deposition and ALP activity in VDN-treated rats when compared with vehicle treatment, which was further confirmed in cultured vascular smooth muscle cells. Concurrently, the loss of smooth-muscle lineage markers and matrix γ-carboxyglutamic acid (Gla) protein (cMGP) in aortas was ameliorated by administering IMD to rats with VC, and the increased phosphor-Smad1/5/8 and core binding factor α-1 levels in calcified vasculature were also reduced. However, the inhibitory effects of IMD on VC were eliminated upon pre-treatment with warfarin or small interfering RNA to reduce cMGP. Conclusion Reduced endogenous IMD levels are associated with increased mineralization in vivo , and administration of IMD inhibits VC development by increasing cMGP levels. IMD may be an endogenous vasoprotective factor for VC.Keywords
This publication has 47 references indexed in Scilit:
- Intermedin (adrenomedullin‐2): a novel counter‐regulatory peptide in the cardiovascular and renal systemsBritish Journal of Pharmacology, 2008
- Osteoprotegerin Inhibits Vascular Calcification Without Affecting Atherosclerosis in
ldlr
(−/−)
MiceCirculation, 2008
- Aortic Msx2-Wnt Calcification Cascade Is Regulated by TNF-α–Dependent Signals in Diabetic Ldlr −/− MiceArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Function and effect of bone morphogenetic protein‐7 in kidney bone and the bone‐vascular links in chronic kidney diseaseEuropean Journal of Clinical Investigation, 2006
- Effects of intermedin1–53 on cardiac function and ischemia/reperfusion injury in isolated rat heartsBiochemical and Biophysical Research Communications, 2005
- Regulatory role of endothelium in the expression of genes affecting arterial calcificationBiochemical and Biophysical Research Communications, 2004
- Intermedin Is a Calcitonin/Calcitonin Gene-related Peptide Family Peptide Acting through the Calcitonin Receptor-like Receptor/Receptor Activity-modifying Protein Receptor ComplexesJournal of Biological Chemistry, 2004
- Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA proteinNature, 1997
- β-Glycerophosphate Accelerates Calcification in Cultured Bovine Vascular Smooth Muscle CellsArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Matrix Gla protein, a new γ-carboxyglutamic acid-containing protein which is associated with the organic matrix of boneBiochemical and Biophysical Research Communications, 1983